News

March 4, 2016

Alpine Institute for Drug Discovery and University of Geneva awarded Swiss CTI grant to discover a novel anti-inflammatory drug

Alpine Institute for Drug Discovery (AiDD) - an enterprise aiming at creating shared value for the community and commercializing academic discoveries with therapeutic potential – and University of Geneva have received a CHF194’000 grant from the Swiss Commission for Technology and Innovation (CTI) to develop an orally available anti-inflammatory agent based on an hitherto unexploited mode of action. AiDD will collaborate with the group of Prof. Leonardo Scapozza of the School of Pharmaceutical Sciences (EPGL) at the University of Geneva. The project will combine AIDD’s early drug discovery assay design and screening capabilities with Prof Scapozza’s pharmaceutical chemistry and biochemistry expertise.

"Orally available, broadly applicable and safe anti-inflammatory drugs based on novel mechanism of action have been much awaited in a field dominated by biologics" noted Prof. Scapozza. "This collaboration with AiDD represents an exciting opportunity to create novel and affordable therapeutic agents that will help fulfilling an important unmet medical need”.

“Through this collaboration with Professor Scapozza’s laboratory, a highly regarded center of excellence in pharmaceutical sciences, we are creating a fertile interface between academic creativity and industrial innovation in Geneva” commented Dr. Thibaut De Smedt, of AiDD.

“This collaboration and CTI grant represent another example of how, by applying an asset-centric approach in a collaborative set-up, AiDD contributes to the emergence of a vivid local biotech ecosystem” commented Dr. Laurent Galibert, of AiDD

About AiDD
The Alpine Institute for Drug Discovery is an enterprise aiming at creating shared value for the community by maintaining industrial know-how in today’s changing pharmaceutical landscape. AiDD’s mission is to maximize the socio-economical impact of academic discoveries by performing translational drug discovery using its cutting-edge discovery platform with academic researchers, technology transfer offices and local incubators to create innovations in the pharmaceutical sector. AIDD’s initial therapeutic focus is immunotherapeutics for oncology and autoimmune/inflammatory diseases.

AIDD initiates projects via public private partnerships and makes its experts and technology suite available to assist academic partners with target identification, characterization and validation efforts. AiDD also manages drug discovery projects through hit-to-lead and lead optimization phases. Through collaborations bridging academia and industry, AIDD aims to be a partner of choice for academics pursuing translational therapeutic discovery and a stable, trusted provider of high-quality pre-medicines for pharmaceutical partners and venture investors.

For more information about AiDD: please contact: info@aidd.ch

About the CTI

The Swiss Commission for Technology and Innovation (CTI) is the Swiss Confederation innovation promotion agency supporting R&D projects, entrepreneurship and the development of start-up companies in Switzerland.

For more information about CTI: see CTI

CTI logo

AIDD UNIGE logos

 

 

February 3, 2016

Fondation Eclosion strengthens an AiDD/UNIGE biotechnology company creation initiative to develop novel treatments in inflammation

Fondation Eclosion - a not-for-profit organization whose mission is to translate life-science innovation developed within our region’s academic Institutions and by entrepreneurs into high potential startup companies, creating economic value and jobs - announced today that it has added its support to a company creation initiative jointly led by the University of Geneva and the Alpine Institute for Drug Discovery (AiDD).

This initiative is centered on an innovative drug discovery program to identify novel drug candidates using allosteric modulation of cell surface receptors to treat inflammation and autoimmune diseases. The consortium is led by Professor Cem Gabay, Head of the Division of Rheumatology, Department of Internal Medicine Specialties, University of Geneva. AiDD will contribute to the industrial maturation of the assets that will serve as the creation of the future local company.

“This initiative brings together scientific excellence, solid industrial know-how and entrepreneurial acumen to yield a well-differentiated product in today’s therapeutic landscape” declared Prof. Gabay.

“Beyond the economic support for its development, Fondation Eclosion’s endorsement rewards efforts to promote a productive public-private interface in the Geneva Canton and illustrates how local actors can productively interact contributing to industrial innovation” commented Raluca Flükiger at UNITEC, the University of Geneva technology transfer office.

“This initiative illustrates the capacity of our region to mobilize forces in translating scientific excellence as developed in our academic institutions into a highly innovative startup company having the potential to offer new therapeutic solutions for patients, with the potential to create value and long-term jobs in the Geneva canton” said Christophe Guichard at Fondation Eclosion.

We are thankful for the Fondation Eclosion’s support and proud to be part of this project that demonstrates the great complementarity of our local biotech entrepreneurial ecosystem”, commented Dr. Luc Otten at AiDD.

About the Fondation Eclosion

The Fondation Eclosion is a life-science driven, not-for-profit organisation supported by the State of Geneva. The Eclosion mission is to assist researchers from Academic Institutions and seasoned life science professionals in translating their discoveries into high potential start-ups companies, developing innovative solutions for patients. Since inception in 2004, the Fondation has contributed to the development of more than 20 start-ups companies in a large range of therapeutic areas (including autoimmune diseases, inflammation, oncology, pulmonary, and fibrotic diseases), and also start-ups companies dedicated to providing services for the pharma industry. More than 100 highly qualified jobs have been created in the start-ups companies supported by the Fondation Eclosion.

Further information can be found at www.eclosion.com

About AiDD

The Alpine Institute for Drug Discovery (AiDD) was founded in 2013 by seasoned industry scientists. AiDD is an enterprise aiming at creating shared value for the community by maintaining industrial know-how in today’s disintegrating pharmaceutical landscape and is currently the unique Institute for Drug Discovery in the Alpine region. The founders have track records in translating novel biology (i.e. academic research) into drug candidates, as well as managing and licensing related intellectual property. AiDD’s mission is to maximize the socio-economical impact of academic discoveries by performing translational drug discovery with academic researchers, technology transfer offices and local incubators to create innovations in the pharmaceutical sector.

For more information about AiDD: please contact: info@aidd.ch

Eclosion-AIDD-UNIGE

 

November 30, 2015

AiDD and iAR to collaborate on transforming academic research into new drug discovery initiatives for arthritis care

The Alpine Institute for Drug Discovery (AiDD) and the Institute for Arthritis Research (iAR) announced today an agreement to identify and develop innovative drug candidates for the treatment of arthritic conditions.

iAR and AiDD will operate according to a risk- and benefit-sharing principle on a project-by-project basis. Scientists from each organization will form an interdisciplinary team for the project advancement. Revenues received from commercialization will be shared with collaborating institutions and academic inventors.

In a first project, AiDD and iAR scientists will work together to develop an orally available drug candidate for treating arthritic patients with unmet clinical needs.

Over the last decade, the therapeutic armamentarium for treatment of arthritic conditions has enriched with the introduction of several biologics. However, a significant number of arthritic patients do not respond to biologic therapies and thus are still in need of efficacious treatments. AiDD and iAR scientists will use an innovative approach to identify drug candidates with a differentiated mechanism of action based on allosteric modulation.

“iAR intends to foster collaborations and combine all necessary expertise to fulfilll its mission of turning research into therapeutics for arthritis care. This alliance with AiDD precisely illustrates this intention” stated Pr. Cem Gabay, head of iAR.

“Both organizations share the same passion for discovery and the same objective to serve patients and the community. We are eager to start working as a team on this new exciting project” says Dr. Galibert of AiDD.

About iAR

iAR is a tax-exempted association founded in 2009 by four leading research institutions in Switzerland and located at the University of Lausanne. iAR’s aim is to turn research into clinical application for arthritis care. The opportunity to include basic research groups as well as laboratories linked to clinical departments is a major strength of iAR that provides the possibility to translate fundamental laboratory discoveries into clinical applications.

The overall objectives are to support fundamental research in arthritis in a national framework with the possibility to develop translational research with an impact into the clinic; and valorization of the fundamental research results by bringing preventive measures, diagnostic and therapy products to the clinic for the patient’s benefit.

For more information about iAR: see iAR

About AiDD

The Alpine Institute for Drug Discovery (AiDD) was founded in 2013 by seasoned industry scientists. AiDD is an enterprise aiming at creating shared value for the community by maintaining industrial know-how in today’s disintegrating pharmaceutical landscape and is currently the unique Institute for Drug Discovery in the Alpine region. The founders have track records in translating novel biology (i.e. academic research) into drug candidates, as well as managing and licensing related intellectual property. AiDD’s mission is to maximize the socio-economical impact of academic discoveries by performing translational drug discovery with academic researchers, technology transfer offices and local incubators to create innovations in the pharmaceutical sector.

For more information about AiDD: please contact: info@aidd.ch

 IAR logo

 

 

July 6, 2015

The Alpine Institute for Drug Discovery (AIDD) gets CHF 100’000 support from the Fondation pour l’Innovation Technologique (FIT) to address unmet medical needs in inflammation

AIDD is the first Institute for Drug Discovery (IDD) in Switzerland - Emerging model for performing innovative early stage drug discovery in collaboration with academic institutions. The supported project aims to develop novel orally available molecules using an innovative multi-dimensional approach to address unmet needs in inflammatory bowel disease, psoriasis, and rheumatoid arthritis. With the support of the FIT, AIDD is collaborating with the University of Geneva to validate the identified hits from the screening campaign against a novel undisclosed target.

 About AIDDs technology platform

AIDDs technology platform offers a new opportunity to tackle new classes of targets through a novel combination of three cutting edge technologies: identification of allosteric pockets with nanobodies, small molecule fragment screening, and the use of ultra-sensitive sensitive functional AURA assays. Synergistic use of these three technologies will help AIDD successfully identify and optimize small molecule therapeutics targeting new classes of targets where previous efforts have failed.

About the FIT

FIT - the Foundation for Technological Innovation - has been helping startups since its inception in 1994 and aims to support high technology and innovative projects by providing appropriate financial assistance. With its financial support, FIT can help complete an initial project or validate a new technology, thereby accelerating the projects commercial development.

For more information about AIDD: see www.aidd.ch and please contact: info@aidd.ch

For more information about AIDD’s novel approach: see technology platform

For more information about FIT: see FIT

 

FIT JPG1

 


July 1, 2015

AIDD awarded at the Alpine High-tech Venture Forum

Luc Otten, business development at AIDD, presented the company at the Alpine High-tech Venture Forum, which took place last June 24-25 in Lausanne, Switzerland. AIDD was among the award winners in the Life Science section (see AHVF).

 AHVF


January 7, 2015

An innovation grant received from Swiss Commission for Technology and Innovation (CTI) to address unmet medical needs in inflammation

Alpine Institute for Drug Discovery (AIDD) and University of Geneva have received a 238’000 CHF grant from the Swiss Commission for Technology and Innovation (CTI) to pursue early stage research on a novel undisclosed target addressing unmet needs in inflammation using a novel and unique multi-dimensional approach. AIDD will collaborate with the laboratory of Professor Leonardo Scapozza of the School of Pharmaceutical Sciences (EPGL) at the University of Geneva to perform assay development, screening, and hit validation.

About AIDD’s novel approach

AIDD’s technology platform offers a new opportunity to tackle new classes of targets through a novel combination of three cutting edge technologies: identification of allosteric pockets with nanobodies, small molecule fragment screening by NMR, and the use of ultra-sensitive sensitive functional AURA assays. Synergistic use of these three technologies will help AIDD successfully identify and optimize small molecule therapeutics targeting new classes of targets where previous efforts have failed.

About the CTI

The Swiss Commission for Technology and Innovation (CTI) is the Swiss Confederation innovation promotion agency supporting R&D projects, entrepreneurship and the development of start-up companies in Switzerland.

For more information about AIDD: see www.aidd.ch and please contact: info@aidd.ch

For more information about AIDD’s novel approach: see technology platform

For more information about CTI: see CTI

CTI logo

 

December 2014

Best wishes for 2015 from AIDD!

Happy new year 2015

 

July 2014

AIDD in the Agefi article "La Vallée de l'avenir".

Agefi July 2014 Health Valley

 

October 2013

The Alpine Institute for Drug Discovery was incorporated in October 2013.